99mTc-放射性药物的现状和展望

分子影像技术和靶向人类疾病不同靶点以及反映特定生物过程的放射性核素标记的分子探针是实现精准医疗的最佳途径。^99mTc-放射性药物与其他SPECT药物以及PET药物在疾病的临床诊断与预后、治疗疗效评估中优势互补，发挥着重要作用。本文概述了临床上正在使用、处于临床试验阶段或临床研究阶段的^99mTc-放射性药物，分析了^99mTc-放射性药物的发展前景和发展趋势，提出继续探索新的靶点，加强基础锝配位化学研究等建议。只有不断研制出反映活体生物化学过程或特异靶向体内生物分子的新型^99mTc-放射性药物，同时发展适于临床使用的^99mTc-标记技术，才能加速新型^99mTc-放射性药物的临床转化，更好地为人类健康服务。

Current Status and Prospects of 99mTc-radiopharmaceuticals

Using molecular imaging techniques, radionuclide-labeled molecular probes can provide noninvasive and real-time visualization of specific biochemical processes in the living humans and pathological process of various human diseases at the molecular level, which will pave the way to precision medicine. ^99mTc-radiopharmaceuticals is playing significant roles in the diagnosis of human diseases and efficacy monitoring of therapeutic strategies together with single photon emission computed tomography imaging modality. This review provided an overview of current status of^99mTc-radiopharmaceuticals used in clinic and clinical trials. Possible future trends in the field of^99mTc-radiopharmaceuticals were discussed. Investigation on the new targets or new biochemical processes as targets and basic technetium chemistry including exploring novel labeling methods and novel technetium building blocks were addressed. Development on the novel^99mTc-radiopharmaceuticals with high affinity, selectivity and specificity for the imaging of unique targets or specific biochemical processes together with^99mTc-labeling methods suitable for clinical use will accelerate the clinical translation of new^99mTc-radiopharmaceuticals.